Monoclonal antibody-based therapy for renal cell carcinoma. Review uri icon

Overview

abstract

  • Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.

publication date

  • August 1, 2003

Research

keywords

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Identity

Scopus Document Identifier

  • 0042821653

PubMed ID

  • 12953760

Additional Document Info

volume

  • 30

issue

  • 3